One important molecular basis for MDR is overexpression of plasma membrane P-glycoprotein (PGP1), which actively extrudes a variety of chemotherapeutic agents from cancer cells, thereby significantly decreasing the efficacy and increasing the side effects of chemotherapeutic drugs (Gillet et al., 2007). This evidence concerns the gene CD44 and cancer.